Calvin C Leung1. 1. Section of Cardiology, Department of Medicine, Orlando VA Medical Center, 13800 Veterans Way, Orlando, FL, 32827, USA. calvin.leung@va.gov.
Abstract
PURPOSE OF REVIEW: Heart failure (HF) remains a significant burden to our healthcare system and a leading cause of hospitalizations. Current reactive strategies to treat and manage HF have failed to reduce hospitalizations and improve survival. The CardioMEMS device has recently been demonstrated to improve quality of life in HF and reduce HF-related hospitalizations. Current HF management strategies are reviewed with a particular emphasis on the current role of the CardioMEMS device. RECENT FINDINGS: The CHAMPION trial is the only randomized trial looking at the CardioMEMS device. Patients managed with targeted pulmonary artery pressures resulted in 28% reduction in the primary end-point of HF-related hospitalization at 6 months (HR 0.72, 95% CI 0.60-0.85, p = 0.0002) and 37% reduction during the entire follow-up period, which averaged 15 months (HR 0.63, 95% CI 0.52-0.77, p < 0.0001). The prospective open-label post-approval study recently presented a 58% reduction in HF hospitalizations per patient year (HR 0.42, 95% CI 0.38-0.47, p < 0.0001). Management of HF using the CardioMEMS device has been shown to reduce HF hospitalizations and improve quality of life regardless of ejection fraction. Patients best suited for this device are those with recurrent congestive symptoms despite optimal medical therapy.
RCT Entities:
PURPOSE OF REVIEW: Heart failure (HF) remains a significant burden to our healthcare system and a leading cause of hospitalizations. Current reactive strategies to treat and manage HF have failed to reduce hospitalizations and improve survival. The CardioMEMS device has recently been demonstrated to improve quality of life in HF and reduce HF-related hospitalizations. Current HF management strategies are reviewed with a particular emphasis on the current role of the CardioMEMS device. RECENT FINDINGS: The CHAMPION trial is the only randomized trial looking at the CardioMEMS device. Patients managed with targeted pulmonary artery pressures resulted in 28% reduction in the primary end-point of HF-related hospitalization at 6 months (HR 0.72, 95% CI 0.60-0.85, p = 0.0002) and 37% reduction during the entire follow-up period, which averaged 15 months (HR 0.63, 95% CI 0.52-0.77, p < 0.0001). The prospective open-label post-approval study recently presented a 58% reduction in HF hospitalizations per patient year (HR 0.42, 95% CI 0.38-0.47, p < 0.0001). Management of HF using the CardioMEMS device has been shown to reduce HF hospitalizations and improve quality of life regardless of ejection fraction. Patients best suited for this device are those with recurrent congestive symptoms despite optimal medical therapy.
Authors: Cynthia Binanay; Robert M Califf; Vic Hasselblad; Christopher M O'Connor; Monica R Shah; George Sopko; Lynne W Stevenson; Gary S Francis; Carl V Leier; Leslie W Miller Journal: JAMA Date: 2005-10-05 Impact factor: 56.272
Authors: Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton Journal: Am Heart J Date: 2005-02 Impact factor: 4.749
Authors: M R Cowie; K F Fox; D A Wood; C Metcalfe; S G Thompson; A J S Coats; P A Poole-Wilson; G C Sutton Journal: Eur Heart J Date: 2002-06 Impact factor: 29.983
Authors: Clyde W Yancy; Margarita Lopatin; Lynne Warner Stevenson; Teresa De Marco; Gregg C Fonarow Journal: J Am Coll Cardiol Date: 2005-12-15 Impact factor: 24.094
Authors: Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen Journal: JAMA Date: 2004-07-21 Impact factor: 56.272